ArticleJournal of diabetes investigation2026
MiR-155-5p promotes endothelial-mesenchymal transition and oxidative stress in diabetic retinopathy.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMicroRNA (miRNA) has been confirmed to be related to gene expression regulation and disease progression. However, the role of miR-155-5p in diabetic retinopathy remains unclear. MATERIALS AND
methodsThe retinal microvascular endothelial cells (RMECs) were treated with high glucose, and then the changes of miR-155-5p, endothelial cell markers (CD31 and VE-cadherin), mesenchymal cell markers (SM22α and α-SMA), and VEGF were detected by RT-qPCR. The apoptotic markers (Bax, Bcl-2, cleaved caspase-3) were detected by Western blotting. Additionally, miRNA inhibitors or small interfering RNA were used to regulate the levels of miR-155-5p and DDAH1. Subsequently, the changes in endothelial-mesenchymal transition markers, oxidative stress markers, and apoptotic proteins were observed. The regulatory relationship between miR-155-5p and DDAH1 was investigated using dual-luciferase reporter assays, RNA immunoprecipitation, and RNA pull-down assays.
resultsAfter culturing RMECs with high glucose, the level of miR-155-5p increased. After the miR-155-5p level was reduced, the levels of CD31 and VE-cadherin increased, while the levels of SM22α, α-SMA and VEGF decreased. Additionally, the downregulation of miR-155-5p significantly inhibited the increase in ROS and Malondialdehyde (MDA) levels as well as cell apoptosis. DDAH1 is the downstream target of miR-155-5p. The downregulation of DDAH1 significantly weakened the inhibitory effects of miR-155-5p downregulation on endothelial-mesenchymal transition, oxidative stress, and cell apoptosis.
conclusionsIn diabetic retinopathy, miR-155-5p affects the endothelial-mesenchymal transition process and oxidative stress levels of RMECs through DDAH1 and reduces cell apoptosis induced by high glucose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.